Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Medical Supplies And Services topic
No spam. Unsubscribe anytime.
Committee backs reimbursement boost to keep home parenteral nutrition pharmacies serving Colorado children
Summary
Senate Bill 84 would increase reimbursement to pharmacies that compound and deliver parenteral nutrition for pediatric patients, intended to stem closures of pharmacies willing to accept Medicaid TPN patients and avoid costly hospital stays.
The House Health & Human Services Committee voted to send Senate Bill 84 to the Appropriations Committee after providers and physicians warned that current reimbursement does not cover the operational cost of preparing and delivering home parenteral nutrition (TPN) for pediatric patients.
Sponsors said the bill creates a temporary increase in the “restocking” reimbursement paid to pharmacies that compound sterile parenteral nutrition, using a statutory cap set at 30 percent as a first‑step incentive to recruit more pharmacies to serve pediatric Medicaid patients. Supporters said one Colorado pharmacy currently accepts Medicaid pediatric TPN patients and that losing that vendor would force children into costly, prolonged hospital stays. Physicians from Children’s Hospital Colorado and home‑infusion clinicians described TPN as a life‑sustaining, individualized IV nutrition therapy that can keep children at home for a fraction of the cost of inpatient care.
Dr. Lindsey Gummer, director of an intestinal rehabilitation program at Children’s Hospital Colorado, testified that many families rely on TPN at home and that the difference between home infusion and inpatient care can be tens of thousands of dollars per episode. Home infusion clinicians and a mother of a TPN‑dependent child described the clinical complexity, specialized training and supply needs for pediatric TPN, and argued the reimbursement gap has driven providers out of the market.
Legislative fiscal staff said an initial stakeholder survey produced a high per-claim administrative cost estimate that produced a large fiscal note; sponsors and HCPF worked with stakeholders and proposed a lower statutory cap to keep the program affordable while recruiting additional pharmacies. The committee adopted no changes and moved the bill to Appropriations with a favorable recommendation.
Why it matters: Pediatric TPN is a highly individualized, sterile compound that many families rely on daily; testimony described a public‑policy choice between supporting a small number of specialized vendors or paying much higher costs when children must be hospitalized.
What’s next: The bill goes to Appropriations for fiscal review; sponsors and HCPF said they will monitor whether the reimbursement change attracts more pharmacies and will report back under Smart Act requirements.
